John Goff, MD
Gastroenterology · Lakewood, CONPI 1942231832
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,533 of the $38,047 with a category attached, or 72.4%. Intercept Pharmaceuticals, Inc. accounts for 75.8% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $19,061 and has fallen 96.3% since, to $696 in 2025. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $150.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$29K
- AbbVie$3K
- Gilead$658
- Takeda Pharmaceuticals U.S.A., Inc.$606
- Johnson & Johnson$547
- E.r. Squibb & Sons, L.L.C.$522
- plus $4K from 28 others
Across 119 payments — averaging $4194.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Braintree Laboratories, Inc.$236K
- Intercept Pharmaceuticals, Inc.$108K
- AbbVie$104K
- Intercept Pharma Europe Ltd.$27K
- Phathom Pharmaceuticals, Inc.$12K
- Gilead$12K
What the payments were for
- Speaking & faculty fees$27,53372%
- Travel & lodging$6022%
- Food & beverage$9,55825%
- Education$3021%
- Gifts$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 29 | $28,851 |
| AbbVie(2 entities) | 81 | $3,180 |
| Gilead | 19 | $658 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $606 |
| Johnson & Johnson(2 entities) | 14 | $547 |
| E.r. Squibb & Sons, L.L.C. | 5 | $522 |
| Boston Scientific | 8 | $463 |
| Phathom Pharmaceuticals, Inc. | 4 | $276 |
| Bristol Myers Squibb | 13 | $247 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $232 |
| Lilly USA, LLC | 3 | $225 |
| Aimmune Therapeutics, Inc. | 2 | $209 |
| Janssen Scientific Affairs, LLC | 2 | $201 |
| Intuitive Surgical | 2 | $200 |
| Pfizer | 10 | $194 |
| Nestle Healthcare Nutrition Inc. | 7 | $179 |
| Sanofi | 4 | $175 |
| Ardelyx, Inc. | 2 | $146 |
| Madrigal Pharmaceuticals | 1 | $132 |
| Bayer | 1 | $125 |
| Novo Nordisk | 1 | $109 |
| Biocompatibles, Inc. | 1 | $93 |
| Braintree Laboratories, Inc. | 3 | $82 |
| Olympus America Inc. | 4 | $71 |
| QOL Medical, LLC | 2 | $44 |
| AstraZeneca | 3 | $42 |
| Digestive Care, Inc. | 1 | $40 |
| Echosens North America, Inc. | 2 | $38 |
| Cook Medical LLC | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Blueprint Medicines Corporation | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| UCB, Inc. | 1 | $26 |
| Shionogi Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,047 in reported general payments places this provider in the 90th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XeljanzTofacitinib Citrate | 28 | $161,904 |
| Humira(Cf) PenAdalimumab | 15 | $100,915 |
| ZenpepLipase/Protease/Amylase | 15 | $27,444 |
| LinzessLinaclotide | 23 | $15,242 |
| Budesonide DrBudesonide | 13 | $4,157 |
| Ursodiol | 15 | $2,607 |
| Esomeprazole Magnesium | 42 | $1,461 |
| Pantoprazole Sodium | 123 | $1,263 |
| Omeprazole | 35 | $727 |
| Azathioprine | 11 | $535 |
| Famotidine | 14 | $274 |
| Dicyclomine Hcl | 17 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXeljanz | $194 | $161,90428 claims |
| Aimmune Therapeutics, Inc.Zenpep | $209 | $27,44415 claims |
| AbbVieLinzess | $3,180 | $15,24223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 304 gastroenterology providers in Colorado.
Other gastroenterology in Lakewood
- Rajesh JainLakewood$239K
- Scott MackenzieLakewood$13K
- Timothy DobinLakewood$12K
- Andrew KorsonLakewood$11K
- Matthew SetoLakewood$11K
- Peter McNallyFt Carson$1.1M
- Douglas AdlerColorado Springs$910K
- Marcelo KugelmasEnglewood$660K
- Mary Ann HuangDenver$408K
- Gareth WeinerThornton$382K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.